The downgrade by a major financial institution like Morgan Stanley from Overweight to Equal-Weight, combined with a significant reduction in the price target, is likely to negatively impact investor sentiment and the stock price of Treace Medical Concepts in the short term. Such a move reflects a change in the firm's outlook on the stock, potentially due to underlying challenges or revised expectations for the company's financial performance or market position.